This peptide is still experimental, and its risk profile is less characterized
In addition, in a cardiovascular outcome study involving patients with type 2 diabetes, of whom more than 80% had a history of cardiovascular disease, semaglutide treatment lowered the rates of 3-point MACE (myocardial infarction, stroke and cardiovascular death) [31]
In 2023, the FDA approved two gene therapies for sickle cell disease
Taking the capsules after meals enriched with healthy fats improves absorption due to the lipid nature of the formulation
This means faster absorption, quicker results, and a stronger impact on overall health
I suspect this is primarily a marketing crackdown, which I have been expecting for a while